Bionomics Ltd (BNOX)

[MiamiGent]

BNOX Recap

I was out looking for a larger whse space yesterday. So, let's examine yesterday's Runner BNOX now to see what we can learn.

Bionomics Limited is a clinical stage biopharmaceutical company. It was up a whopping 570% at one point yesterday, hitting two of our five positive scans we follow each morning: Most Actives #1 and Highest % Gainers #1. It closed regular session up 240%.

The paramount question with Runners is, "is it somewhat warranted (somewhat bc 570% is rarely warranted) or is a POS stock the "boys" got hold of, as stuffy was wont to say.

The News: Why Is Stress Disorder Focused Bionomics Stock Trading Higher Today?
BENZINGA 8:24 AM ET Sep-28-2023

Bionomics Limited (NASDAQ:BNOX) announced topline results from its Phase 2b ATTUNE trial of BNC210 for post-traumatic stress disorder (PTSD).

The trial met its primary endpoint of change in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity score from baseline to Week 12 (p=0.048).

A statistically significant change in CAPS-5 score was also observed at Week 4 (p=0.015) and at Week 8 (p=0.014).

Treatment with BNC210 also showed statistically significant improvement in clinician-administered and patient self-reporting in two of the trial's secondary endpoints.

Specifically, BNC210 led to significant improvements at Week 12 in depressive symptoms (p=0.040) and sleep (p=0.041) as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and Insomnia Severity Index (ISI), respectively.

BNC210 also showed signals and trends across visits in the other secondary endpoints, including the clinician and patient global impression-symptom severity (CGI-S, PGI-S) and the Sheehan Disability Scale (SDS).

Treatment with 900 mg twice daily BNC210 had a favorable safety and tolerability profile.

Additionally, the Company recently held a Phase 3-enabling End-of-Phase 2 meeting with the FDA to advance BNC210 for the acute treatment of social anxiety disorder into registrational studies and is awaiting receipt of the formal meeting minutes.

Price Action: BNOX shares are up 387.30% at $4.80 during the premarket session on the last check Thursday.


That's significant news. Phase one is just to prove taking the candidate doesn't make you spin around three times and fall to the floor like a wood plank. Phase Two proves efficacy or not and Bionomics reported it met all endpoints, So, the pop was warranted.

Present trading: BIONOMICS LTD $2.9498 -0.4202 (-12.47%)
As of Sep-29-202311:01:17 AM ET

Volume 4,435,157

10/90-day avg. vol. - 13M / 2M

https://stockcharts.com/h-sc/ui?s=BNOX

Day range $2.83 - $3.56

52-week range $0.9300 - $10.90

MG for $Stock*Shop*Charts*News*Option$ board